Patient Experience Matters

I recently broke my prescription glasses and was forced to purchase a new frame from a local eyeglasses provider.  At the same time, I also had to visit my pharmacy to refill a prescription for my daughter. The striking difference in my experience has inspired me to write this post. Continue reading Patient Experience Matters

Advertisements

Opioid Withdrawal Symptoms – “Oozing from the Orifices”

I am happy to see some of my patients’ opioid therapies being tapered down. Last week, I went to a talk on Opioid Use Disorder. The speaker described the opioid withdrawal symptoms as “oozing from the orifices”.  I agree this description wholeheartedly! When opioids are tapered too quickly, it can cause tearing eyes, runny nose and diarrhea…..

Continue reading Opioid Withdrawal Symptoms – “Oozing from the Orifices”

How will Drug coverage change on Jan 1 2018 for Children and Youth?

If you live in Ontario, OHIP Plus will be effective as of Jan 1, 2018 which means the Ontario Drug Benefits Program will pay for a number of prescription medications for anyone below the age of 25. So what do you really need to know?

Continue reading How will Drug coverage change on Jan 1 2018 for Children and Youth?

Direct-to-Consumer Advertising or Public Health Awareness?

Recently, many primary health providers have been bombarded with questions about the latest shingles vaccine, Shringrix made by GlaxoSmithKline.

Continue reading Direct-to-Consumer Advertising or Public Health Awareness?

6 Things Pharmacists and Patients Should Question – Choosing Wisely Canada

Pharmacists have finally developed the following 6 things to question in partnership with Choosing Wisely Canada:

Continue reading 6 Things Pharmacists and Patients Should Question – Choosing Wisely Canada

DOAC Dual or Triple Therapy for Atrial Fibrillation after Percutaneous Coronary Intervention

For individuals with atrial fibrillation who also require percutaneous coronary intervention, triple antithrombotic therapy with warfarin and two antiplatelet agents (e.g. Aspirin and Clopidogrel) has been the standard of care for post PCI management. However, this combination therapy is also associated with higher risk of bleeding.  Recently, many research scientists have started looking at the utility of dual therapy with DOAC and a P2Y12 inhibitor such as clopidogrel or ticagrelor in the same setting.  These results have finally been released for rivaroxaban and dabigatran.

Continue reading DOAC Dual or Triple Therapy for Atrial Fibrillation after Percutaneous Coronary Intervention

Medscheck – Adding Value Effortlessly

I have come across few Medschecks completed in the community where I have felt slightly perplexed.  Many Medscheck documentation would include a notification that a Medscheck has been completed but no issues have been identified but I could easily identify 3-4 potential issues just from glancing at the medication list. Some have not even included a personal medication record which, to my knowledge, is a requirement for the Medscheck Program.

Continue reading Medscheck – Adding Value Effortlessly